Page 5 - Ouse Model News Today

Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences and Beijing Chaoyang Hospital have developed a new "pseudo cell" formulation based on self-healing microcapsule-loading exosomes to treat diverse vitreoretinal diseases.

Researchers from North Carolina State University have pinpointed a particular peptide's role in activating atopic dermatitis, or eczema. The work could lead to more effective treatments for the condition.

Different strains of E.coli can outcompete one another to take over the gut, a new study reveals.

The first step in the development of the allergic conjunctivitis is the penetration of the allergen through the epithelial layer.

The study evaluates the efficacy of a new quadrivalent mRNA influenza vaccine, finding it to be highly immunogenic and protective in a mouse model. Compared to traditional vaccines, the mRNA-based option offers advantages like reduced production time and elimination of the risk of growth-promoting mutations.

In a study published in the journal Genes & Diseases, researchers from Army Medical University and Shenzhen University investigated the pivotal role of miR-18a-5p, a microRNA, in the development and progression of osteoblastic lesions resulting from prostate cancer (PCa) bone metastasis.

Before SARS-CoV-2 and the COVID-19 pandemic, there was the Zika virus epidemic, lasting from 2015 to 2016. The Zika virus can cause serious birth defects and abnormalities.

Researchers at the University of Michigan have developed a model for studying one type of familial epilepsy, opening the door to understanding—and eventually targeting—the mechanisms that lead to the disorder and its associated fatalities.

Discovery from the lab of Youyang Zhao, PhD, from Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago offers promising treatment approaches for acute respiratory distress syndrome (ARDS) in the elderly that can be caused by severe COVID-19, pneumonia, flu or sepsis. Currently there are no pharmacological or cell-based treatments for ARDS.

Researchers at the University of Chicago Medicine Comprehensive Cancer Center established "proof-of-concept" for a new treatment approach that was able to effectively treat the most aggressive forms of prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.